5 stories mentioning INDVUpdated 21m ago
Every FINWIRES story that references INDV, newest first.
Indivior (INDV) has an average rating of buy and mean price target of $50.83, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Ryan Preblick, Chief Financial Officer, on June 08, 2026, sold 36,000 shares in Indivior Pharmaceuticals (INDV) for $1,357,200. Following the Form 4 filing with the SEC, Preblick has control over a total of 284,751 common shares of the company, with 284,751 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1625297/000201486626000011/xslF345X05/wk-form4_1781085864.xml
Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.Indivior Pharmaceuticals (INDV) shares were up more than 2% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.Axsome Therapeutics (AXSM) stock was up more than 3% after the company reported higher Q1 revenue while its loss per share increased.ADMA Biologics (ADMA) shares were 0.8% higher after the company said it received US Food and Drug Administration approval for the supplemental biologics license application to expand the label of its Asceniv therapy.
Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.Indivior Pharmaceuticals (INDV) shares were up more than 3% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.
Indivior Pharmaceuticals (INDV) shares were rising past 4% in Thursday trading after it reported Q1 adjusted earnings and net revenue that rose year on year and beat analysts' estimates, and also lifted its 2026 net revenue guidance.The company reported Q1 adjusted earnings Thursday of $0.96 per diluted share, up from $0.45 a year earlier.Analysts polled by FactSet expected $0.66.Net revenue for the quarter ended March 31 was $317 million, up from $266 million a year earlier.Analysts surveyed by FactSet expected $272.8 million.The company said it now expects 2026 net revenue of $1.215 billion to $1.285 billion, up from its previous outlook of $1.125 billion to $1.195 billion.Analysts polled by FactSet expect $1.16 billion.Price: $35.94, Change: $+1.79, Percent Change: +5.24%
